Phenotypes Associated with This Genotype

Genotype
MGI:5699839

• Allelic Composition: Tg(PDGFB-SNCA*A53T)8Ema/0
• Genetic Background: Not Specified

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

abnormal motor capabilities/coordination/movement ( J:227112 )

• mice develop progressive motor deficits

homeostasis/metabolism

decreased serotonin level ( J:226922 )

• 5-HT levels are reduced within the brainstem, including the rostral raphe nuclei

• however, loss of serotonergic neurons is not seen

decreased physiological sensitivity to xenobiotic ( J:226922 )

• the fluoxetine-mediated increase in hippocampal doublecortin+ neuroblast densities is less pronounced in mutants than in controls, indicating a reduced response to fluoxetine treatment within the dorsal dentate gyrus

nervous system

abnormal nervous system morphology ( J:226922 , J:227112 )

• alpha-synuclein accumulation is seen the perikarya of brainstem median, dorsal raphe neurons, and in the granule cell layer and the subgranular zone of the dentate gyrus (J:226922)

• mice show accumulation of alpha-synuclein in synapses and neurons, however few or no inclusions are seen (J:227112)

abnormal innervation ( J:226922 )

• serotonergic innervation of the dorsal infrapyramidal blade is reduced, with an approximate 48% reduction in total SERT+ fiber length

• innervation of the suprapyramidal blade is lower in the ventral part of the hippocampus

alpha-synuclein inclusion body ( J:226922 )

• serotonergic neurons show intracellular inclusions of alpha-synuclein within median and dorsal raphe nucleus neurons at 12 months of age

neurodegeneration ( J:227112 )

• mice develop progressive neurodegeneration

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Parkinson's disease 1		DOID:0060367	OMIM:168601	J:226922